Advertisement
POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy
POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.
Jose Sousa
Exciting research but still in its infancy, the following sentence "But two people (12%) who received all seven antibody doses still maintained viral suppression after one year." shows that it is more frequent treatment than the newly approved one injection every second month of ART. And only 12% suppression means Gilead has a lot of research ahead although I can see that it might be a benefit (if studied) in a very small population, hopefully it might help those with multi-class resistance.
May 12, 2022 • Montreal